A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran

Xuebing Wu, Jing Zhang · 2026

Read A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran by Xuebing Wu, Jing Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13540009.txt.

Description

Xuebing Wu and Jing Zhang reviewed a gene-silencing drug for high cholesterol in a 2026 paper. Fatty artery disease kills widely, and cutting the harmful cholesterol fraction prevents events. Yet most patients miss their targets: daily statins burden users, some cannot tolerate them, and antibody drugs need frequent shots.

The reviewed drug is the first of its kind, a small RNA that switches off a liver protein that clears cholesterol poorly. The review covers how it works, its trial record, safety, and use in special groups like kidney patients. Dosing is rare, which may help patients stay on track. The authors present it as a landmark option, with care advice for clinics adopting it.

Catalog record

CREATORXuebing Wu, Jing Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13540009

Browse the full library · About the Tower of Babel